A Carnero

Summary

Country: Spain

Publications

  1. ncbi PTEN, more than the AKT pathway
    Carmen Blanco-Aparicio
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Carcinogenesis 28:1379-86. 2007
  2. ncbi The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications
    Amancio Carnero
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Curr Cancer Drug Targets 8:187-98. 2008
  3. ncbi The PKB/AKT pathway in cancer
    Amancio Carnero
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Curr Pharm Des 16:34-44. 2010
  4. ncbi High throughput screening in drug discovery
    A Carnero
    Experimental Therapeutics Programme, CNIO, Madrid, Spain
    Clin Transl Oncol 8:482-90. 2006
  5. pmc Characterization of the p53 response to oncogene-induced senescence
    Lidia Ruiz
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    PLoS ONE 3:e3230. 2008
  6. pmc Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators
    Fabian Zanella
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    BMC Cell Biol 10:14. 2009
  7. ncbi Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation
    Amancio Carnero
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Oncogene 23:6006-11. 2004
  8. doi Novel inhibitors of the PI3K family
    Amancio Carnero
    Centro Nacional de Investigaciones Oncologicas, Experimental Therapeutics Program, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain
    Expert Opin Investig Drugs 18:1265-77. 2009
  9. ncbi Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription
    V Cepero
    CNIO, Experimental Therapeutics Program, Madrid, Spain
    Clin Transl Oncol 9:521-30. 2007
  10. ncbi Cellular senescence bypass screen identifies new putative tumor suppressor genes
    J F M Leal
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Oncogene 27:1961-70. 2008

Collaborators

  • Oliver Renner
  • R Perona
  • A Cascon
  • Juan F Poyatos
  • B R Henderson
  • Fabian Zanella
  • Matilde E Lleonart
  • Paolo Pevarello
  • Marcos Malumbres
  • Wolfgang Link
  • Cristina Rodriguez-Antona
  • J C Lacal
  • Guido Kurz
  • Hiroshi Kondoh
  • Jesus Gil
  • Julen Oyarzabal
  • Jing Wang
  • Christer Betsholtz
  • Lorenzo A Pinna
  • Carmen Blanco-Aparicio
  • Juan F M Leal
  • Victoria Moneo
  • Maria E Castro
  • Maria V Guijarro
  • Irene Ferrer
  • Santiago Ramon Y Cajal
  • Aranzazu Rosado
  • M V Guijarro
  • Jelena Urosevic
  • Magdalena Zajac
  • Lidia Ruiz
  • J F M Leal
  • Belén Pequeño
  • M E Castro
  • Carmen Navarro-Ranninger
  • V Cepero
  • Ana M González-Vadillo
  • V Quereda
  • Francisco J Ramos-Lima
  • Fernando Blanco
  • V Moneo
  • Mariano Barbacid
  • Jesus Fominaya
  • Nerea Martinez
  • Stephane Bach
  • Rocio Sotillo
  • David Bernard
  • Maria del Valle Guijarro
  • Yolanda Cecilia
  • Marta Canamero
  • Eleanor Y M Sum
  • Matthias Drosten
  • Mercedes Becerra
  • Alma Dhawahir
  • Magali Traskine
  • Beatriz Garcia
  • D H Beach
  • J Fominaya
  • C Blanco-Aparicio
  • Beatriz Martinez-Delgado
  • Mercedes Robledo
  • M Robledo
  • Maria Victoria Moneo
  • Estrella Castro
  • Javier Benitez
  • Marcelline Kaufman
  • S Ramon Y Cajal
  • Adoracion G Quiroga
  • Amparo Alvarez-Valdés
  • L Romero
  • Josep Castellvi
  • A Alvarez-Valdes
  • P Dubus
  • Beatriz García-Serrelde
  • Raquel G Díaz
  • A M González-Vadillo
  • B García-Serrelde
  • J Martinalbo
  • C Navarro-Ranninger
  • Soledad Alonso
  • F Blanco
  • Marie Knockaert
  • Jens Reinhardt
  • Mercedes Navarrete
  • Marcel Koken
  • Frank Totzke
  • Jose Jimeno
  • Gordon Peters
  • Stephen P Coburn
  • Yongqin Wan

Detail Information

Publications49

  1. ncbi PTEN, more than the AKT pathway
    Carmen Blanco-Aparicio
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Carcinogenesis 28:1379-86. 2007
    ..However, AKT is more than a passive bridge toward PTEN tumorigenesis, since its expression not only allows but also enforces and accelerates the tumorigenic process in combination with other oncogenes...
  2. ncbi The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications
    Amancio Carnero
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Curr Cancer Drug Targets 8:187-98. 2008
    ..Additionally, the binding of PI3K to oncogenic ras is essential for the transforming properties of ras. In summary, the data strongly support the view of the PTEN/PI3K/AKT pathway as an important target for drug discovery...
  3. ncbi The PKB/AKT pathway in cancer
    Amancio Carnero
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Curr Pharm Des 16:34-44. 2010
    ..These proteins are kinases, which are very "druggable" targets a priori, and, according to the "addiction hypothesis", cancer cells with the activated pathway will be more dependent on its activity for their survival...
  4. ncbi High throughput screening in drug discovery
    A Carnero
    Experimental Therapeutics Programme, CNIO, Madrid, Spain
    Clin Transl Oncol 8:482-90. 2006
    ..To that end, new developments in large-scale cell biology and compound library design in silico have evolved to obtain data with higher predictability of clinical efficacy...
  5. pmc Characterization of the p53 response to oncogene-induced senescence
    Lidia Ruiz
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    PLoS ONE 3:e3230. 2008
    ..It is a live debate whether these outcomes are influenced by quantitative or qualitative mechanisms. Furthermore, the relative contribution of p53 to Ras-induced senescence is also matter of controversy...
  6. pmc Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators
    Fabian Zanella
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    BMC Cell Biol 10:14. 2009
    ..We developed U2transLUC, an assay system in which luciferase and fluorescent read-outs can be multiplexed to provide a powerful cell-based high content screening method...
  7. ncbi Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation
    Amancio Carnero
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Oncogene 23:6006-11. 2004
    ..Thus, the reciprocal cooperation between myc and ras in a p21-null background during cellular immortalization lead to increased oncogenic cooperation between ras and myc...
  8. doi Novel inhibitors of the PI3K family
    Amancio Carnero
    Centro Nacional de Investigaciones Oncologicas, Experimental Therapeutics Program, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain
    Expert Opin Investig Drugs 18:1265-77. 2009
    ..Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the PI3K pathway at different points. In this work, we review the targeting of PI3K protein for therapeutical intervention...
  9. ncbi Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription
    V Cepero
    CNIO, Experimental Therapeutics Program, Madrid, Spain
    Clin Transl Oncol 9:521-30. 2007
    ..One line of work is focussed on trans platinum complexes, some of which exhibit antitumour activity similar to or even higher than that of their cis counterparts...
  10. ncbi Cellular senescence bypass screen identifies new putative tumor suppressor genes
    J F M Leal
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Oncogene 27:1961-70. 2008
    ..Our data suggest that the three genes identified in the genome-wide loss-of-function genetic screen are putative tumor suppressors located at 15q21.2; 7q35 and 14q32.33...
  11. doi Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells
    F Zanella
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid 28029, Spain
    Oncogene 29:2973-82. 2010
    ..Altogether, our results show the potential of large-scale cell-based RNAi screens to identify promising diagnostic markers and therapeutic targets...
  12. ncbi Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissue
    Oliver Renner
    Experimental Therapeutics Programme, Spanish National Cancer Centre, E 28029 Madrid, Spain
    J Cell Biochem 95:859-67. 2005
    ....
  13. ncbi Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis
    Juan F Poyatos
    Evolutionary Systems Biology Initiative, Structural and Computational Biology Program, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, Madrid 28029
    J Theor Biol 230:333-41. 2004
    ..The models introduced, though simple, help to integrate experimental information relating tumorigenesis with cellular and organism aging phenomena...
  14. pmc Targeting the cell cycle for cancer therapy
    A Carnero
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas CNIO, c Melchor Fernandez Almagro no 3, 28029 Madrid, Spain
    Br J Cancer 87:129-33. 2002
    ..Thus, although too early to provide a cell cycle target based new commercial drug, there is no doubt that it will be an excellent source of new anticancer compounds...
  15. ncbi Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria
    Carmen Blanco-Aparicio
    Experimental Therapeutics Programme, Spanish National Cancer Center CNIO, Madrid, Spain
    Anticancer Drugs 16:977-87. 2005
    ..These results facilitate the exploration of potential synergism between chemotherapeutic treatment and the search for others that can account for similar molecular mechanisms of cooperation...
  16. pmc Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases
    Wolfgang Link
    From the Experimental Therapeutics Programme, Spanish National Cancer Research Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    J Biol Chem 284:28392-400. 2009
    ..This leads to the synthesis of ETP-45658, which is a potent and selective inhibitor of phosphoinositide 3-kinases and demonstrates mechanism of action in tumor cell lines and in vivo in treated mice...
  17. ncbi MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation
    Maria V Guijarro
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, Madrid 28029, Spain
    Carcinogenesis 28:2443-50. 2007
    ..Our data indicate that MAP17 protein activates AKT through ROS and this is determinant to confer resistance to Myc-induced apoptosis in the absence of serum...
  18. ncbi Genetic modelling of the PTEN/AKT pathway in cancer research
    Oliver Renner
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, Madrid, Spain
    Clin Transl Oncol 10:618-27. 2008
    ..This review will summarise some of the key animal models which have helped us to understand this signalling network and its contribution to tumorigenesis...
  19. ncbi Targeted search for anticancer drugs--CNIO cancer conference. 16-18 March, Madrid, Spain
    Juan Carlos Lacal
    Instituto de Investigaciones Biomedicas, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
    IDrugs 6:437-41. 2003
    ....
  20. ncbi Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate
    Oliver Renner
    Experimental Therapeutics Programme, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro3, Madrid, Spain
    Carcinogenesis 28:1418-25. 2007
    ..Since they define overlapping but not identical subsets of the tested tissue panel, a combination of all four markers might lead to a more accurate diagnosis of the status of the PI3K-signaling cascade in cancer patients...
  21. ncbi Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression
    V Quereda
    Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Oncogene 26:7665-74. 2007
    ....
  22. ncbi Overexpression of PKC zeta in NIH3T3 cells does not induce cell transformation nor tumorigenicity and does not alter NF kappa B activity
    S Montaner
    , CSIS, Madrid, Spain
    Oncogene 10:2213-20. 1995
    ..Thus, mammalian PKC zeta is most likely not directly involved in the regulation of cell proliferation in fibroblasts nor affects directly or indirectly the activation of NF kappa B...
  23. ncbi Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrest
    M V Guijarro
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    J Cell Biochem 101:112-21. 2007
    ..However, MAP17 mRNA expression did not correlate with TNF resistance. Our data indicates that although MAP17 expression might bypass TNF-induced growth arrest, it is not the only determinant of this response...
  24. doi Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening
    Fabian Zanella
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Chembiochem 9:2229-37. 2008
    ..Our data illustrate the potential of chemical genetics when combined with robust and sensitive high-content-screening technology...
  25. ncbi Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt
    Wolfgang Link
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain
    J Cell Biochem 95:979-89. 2005
    ..p110 isoform-mediated protection from cell death was abrogated upon expression of a kinase-negative version of Akt...
  26. doi Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation
    Oliver Renner
    Experimental Therapeutics Program and Biotechnology Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Cancer Res 68:9643-53. 2008
    ....
  27. doi Using cells devoid of RAS proteins as tools for drug discovery
    Jelena Urosevic
    Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Mol Carcinog 48:1038-47. 2009
    ..The use of cell lines whose proliferative properties exclusively depend on selective targets provide a novel strategy to analyze the specificity of selective inhibitors designed against molecular targets implicated in human cancer...
  28. ncbi Mouse models to decipher the PI3K signaling network in human cancer
    Oliver Renner
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Curr Mol Med 9:612-25. 2009
    ..Using these models for drug testing may enable more accurate prediction of the effects that a specific drug will have on a patient...
  29. ncbi Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts
    Maria E Castro
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro, 3, 28029, Madrid Spain
    J Cell Biochem 92:514-24. 2004
    ..Our results indicate that oncogenic activation of the Ras pathway in murine fibroblasts converts p53 into a senescence inducer through a p21waf1-independent mechanism...
  30. ncbi Adding more content to screening: reactivation of FOXO as a therapeutic strategy
    Fabian Zanella
    Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
    Clin Transl Oncol 11:651-8. 2009
    ..Here, we review the development of HCS platforms to identify molecules influencing FOXO nuclear relocation and activation as pharmacological targets, their applicability and the future directions of the screening field...
  31. pmc Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models
    Carmen Blanco-Aparicio
    Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
    PLoS ONE 5:e9305. 2010
    ....
  32. ncbi Overexpression of cyclin D1 inhibits TNF-induced growth arrest
    Victoria Moneo
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain
    J Cell Biochem 89:484-99. 2003
    ..Our results confirm that p21(waf1) has an essential role in TNF-induced arrest and that the deregulation of cyclin D1 may be one of the mechanisms to escape physiological signals to restrict tumoral growth...
  33. doi Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function
    Maria E Castro
    Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas, C Melchor Fernández Almagro, 3, 28029 Madrid, Spain
    Carcinogenesis 29:1343-50. 2008
    ..Interestingly, in most cases, the reduction of ribosomal protein mRNAs occurs only to 50%. Our data suggest that ribosomal protein imbalance might contribute to p53 regulation through the ribosomal biogenesis checkpoint...
  34. ncbi An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays
    Fabian Zanella
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Assay Drug Dev Technol 5:333-41. 2007
    ..76. In summary, U2nesRELOC is a cell-based nuclear export assay suitable for high throughput screening, providing counterscreens for pathway deconvolution...
  35. ncbi Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas
    Cristina Rodriguez-Antona
    Hereditary Endocrine Cancer Group, Spanish National Cancer Centre, c Melchor Fernandez Almagro no 3, 28029 Madrid, Spain
    Blood 110:3345-51. 2007
    ..In conclusion, a high CYP3A4 tumoral expression could be useful to predict poor response to the standard PTCL chemotherapy; in these cases alternative chemotherapy combinations or doses should be explored...
  36. doi PPP1CA contributes to the senescence program induced by oncogenic Ras
    Maria E Castro
    Experimental Therapeutics Programme, Spanish National Cancer Research Center CNIO, 28029 Madrid, Spain
    Carcinogenesis 29:491-9. 2008
    ..We propose that oncogenic stress induced by ras causes ceramide accumulation, therefore, increasing PPP1CA activity, pRb dephosphorylation and onset of the p53-induced arrest, contributing to tumor suppression...
  37. ncbi Understanding FOXO, new views on old transcription factors
    Fabian Zanella
    Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain
    Curr Cancer Drug Targets 10:135-46. 2010
    ..Therefore, understanding the modulation of FOXO transcription factors will allow the design of new compounds with antitumor potential...
  38. ncbi MAP17 enhances the malignant behavior of tumor cells through ROS increase
    Maria V Guijarro
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain
    Carcinogenesis 28:2096-104. 2007
    ..Our work shows the tumorigenic capability of MAP17 through a connection between Na+-coupled co-transporters and ROS...
  39. ncbi Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity
    Rocio Sotillo
    Molecular Oncology, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
    Cancer Res 65:3846-52. 2005
    ..These data suggest that genetically engineered tumor models involving key cell cycle regulators are a valuable tool to evaluate drugs with potential therapeutic benefit in human cancer...
  40. pmc A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling
    Aranzazu Rosado
    Experimental Therapeutics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    PLoS ONE 3:e1823. 2008
    ..However, rational target-orientated approaches to cell based drug screens for anti-cancer agents have historically been compromised by the notorious absence of suitable control cells...
  41. doi Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines
    Magdalena Zajac
    Grupo Genética Humana, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, Madrid, Spain
    Mol Cancer Ther 7:2358-66. 2008
    ..Our observations show that BRCA1 mediates G(2)-M transition mainly through chek1 on 17-allyloamino-17-demethoxy-geldanamycin treatment...
  42. ncbi Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death
    Ana M González-Vadillo
    Departamento de Quimica Inorganica, Facultad de Ciencias, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain
    J Inorg Biochem 101:551-8. 2007
    ..Mechanistically, the antitumor activity correlates with a blockade of the cell cycle in S phase and a complete abolishment of G2/M checkpoint arrest suggesting physical interaction of compound with DNA inhibiting S phase transition...
  43. ncbi Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
    Nerea Martinez
    Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas, C Melchor Fernandez Almagro 3, E 28029 Madrid, Spain
    Mol Cancer Ther 4:814-23. 2005
    ..The transcriptional signature described here may lead to the identification of ET-743 downstream mediators and transcription regulators and the proposal of strategies by which ET-743-sensitive tumors may be identified...
  44. ncbi Cell cycle deregulation: a common motif in cancer
    Marcos Malumbres
    Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas, Madrid
    Prog Cell Cycle Res 5:5-18. 2003
    ..Manipulation of these control mechanisms provides new avenues for the design of advanced therapeutic strategies against tumor development...
  45. ncbi Glycolytic enzymes can modulate cellular life span
    Hiroshi Kondoh
    Wolfson Institute for Biomedical Research, University College London, London Research Institute, London, United Kingdom
    Cancer Res 65:177-85. 2005
    ..Because wild-type p53 down-regulates PGM, mutation of p53 can facilitate immortalization via effects on PGM levels and glycolysis...
  46. ncbi Roscovitine targets, protein kinases and pyridoxal kinase
    Stephane Bach
    CNRS, Cell Cycle Group, UPS 2682 and UMR 2775, Station Biologique, BP 74, 29682 Roscoff Cedex, Bretagne, France
    J Biol Chem 280:31208-19. 2005
    ..These results could help in interpreting the cellular actions of (R)-roscovitine but also in guiding the synthesis of more selective roscovitine analogs...
  47. ncbi Immortalization of primary human prostate epithelial cells by c-Myc
    Jesus Gil
    Molecular Oncology Laboratory, Cancer Research UK, London Research Institute, United Kingdom
    Cancer Res 65:2179-85. 2005
    ..These results give a partial explanation for the physiologic role of c-Myc overexpression in prostate cancer...
  48. ncbi CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus
    David Bernard
    Laboratory of Molecular Virology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium
    Oncogene 24:5543-51. 2005
    ..Together, these data suggest that CBX7 represses p16Ink4a and p14Arf expression in normal and tumor-derived prostate cells, affecting their growth depending on the status of the p16Ink4a/Rb and the p14Arf/p53 pathways...
  49. ncbi New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin
    Francisco J Ramos-Lima
    Departamento de Quimica Inorganica, Universidad Autonoma de Madrid, 28049 Madrid, Spain
    J Med Chem 50:2194-9. 2007
    ..Our data indicate that our compounds are not cross-resistant with cisplatin and might be promising agents in the treatment of tumors unresponsive to cisplatin...